Table 1 Baseline characteristics of study participants
From: Development of ATAQ-LAM: a tool to assess quality of life in Lymphangioleiomyomatosis
Variable | N | Results |
|---|---|---|
Female | 69 | |
Age in years | 69 | 49.1 ± 12.0 (range 24 – 73) |
Race | 68 | |
African-American | 2 | |
Asian | 3 | |
Hispanic | 5 | |
White | 58 | |
Education | 65 | |
High-school | 2 | |
Some college | 10 | |
Trade school graduate | 2 | |
College graduate | 28 | |
Masters | 18 | |
Doctorate | 5 | |
Employment | 64 | |
Full-time | 26 | |
Part-time | 8 | |
Retired | 8 | |
Disabled | 14 | |
Unemployed | 8 | |
Smoking history | 67 | |
Current | 0 | |
Former | 18 | |
Never | 49 | |
LAM duration, years | 69 | 8.2 ± 7.9 (range 0.03 – 40) |
FEV1, L | 17 | 1.70 ± 0.6 (range 0.79 – 2.87) |
FEV1% | 17 | 65.1 ± 22.5 (range 32 – 95) |
Supplemental oxygen | 67 | |
Never | 38 | |
Ever | 29 | |
Sleep only | 2 | |
Exertion only | 9 | |
Sleep + exertion, not at rest | 12 | |
All the time | 6 | |
Medications | ||
Combination CS/LABA | 26 | |
Doxycycline | 1 | |
Plaquenil | 1 | |
Rapamycin | 30 | |
Statin | 18 |